Phentermine, an FDA-approved appetite suppressant since 1959, works through central nervous system stimulation, while tirzepatide (Zepbound, Mounjaro), approved in 2023 for obesity, operates through dual GIP/GLP-1 receptor pathways
When your total dinner intake is only 400 to 600 calories, spending a third of that budget on drinks means protein falls short
By activating both pathways, Tirzepatide can help control appetite, reduce food intake, and improve glucose metabolism, which can lead to significant weight loss
These are often seen in individuals with thyroid problems
Losing weight is a significant achievement, but many people experience skin changes after their transformation
Its key feature is enhancing natural GLP-1 hormone activity, which helps users feel fuller while maintaining digestive comfort